Fiona Hamilton Marshall: These are hopeful findings for patients with relapsed/refractory diffuse large B-cell lymphomawho may not have a durable response to existing therapies.

Quoting Fiona Hamilton Marshall, President of the Novartis Institute for BioMedical Research, on LinkedIn:

“Excited to share this Cancer Discovery paper detailing the preclinical development and preliminary clinical data on our investigational CAR T cell therapy in adults with relapsed/refractory diffuse large B-cell lymphoma. The work to date suggests that the treatment, which utilizes our next-generation cell therapy platform, T-Charge, to significantly decrease manufacturing time, can potentially preserve T-cell stemness, enhance CAR T-cell expansion, maintain a favorable safety profile at lower doses, and help control disease progression.

Congratulations to all involved on the publication. These are hopeful findings for patients with r/r DLBCL who may not have a durable response to existing therapies.”

For the article click here.
Source: Fiona H. Marshall/LinkedIn.